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Blood diseases are distinctive group of inherited and acquired, benign and 
malignant, acute and chronic disorders with diverse incidence, etiology, pathogen-
esis, and prognosis.
In the early days of hematology-oncology practice, hematology dominated and 
occupied most of the practitioner’s time because most patients with cancer had a 
short life span and limited therapeutic modalities were available [1].
Our understanding of hematologic conditions has advanced considerably with 
the explosion of molecular biology and the management of most hematologic 
conditions has kept pace with these scientific advances. It has been a privilege to 
be a witness and participant in this great evolution over the last years where blood 
disorders have been studied extensively through many laboratory approaches for 
example, microscopy, clinical chemistry, immunophenotyping, genetic tests such as 
conventional cytogenetics, fluorescence in situ hybridization (FISH), and poly-
merase chain reaction (PCR). Yet we still have a long way to go as current advances 
are superseded by therapy based upon the application of knowledge garnered from 
an accurate understanding of the fundamental biology of hematological diseases [2].
Application of these advanced diagnostic tools had clarified the greatest involve-
ment of different molecular mechanisms in the pathological transformation of hema-
topoietic progenitor cells and disease progression in many hematological diseases. 
Interestingly, more precise and accurate diagnosis was established, also, patients risk 
stratification as well as discovery of personalized, tailored therapeutic approach [3].
Aplastic anemia is a disease in which the stem cell fails to maintain bone marrow 
production. Aplastic anemia may be caused by hereditary disorders that usually 
present in childhood or in young adults (e.g., Fanconi anemia), or may present as 
an idiopathic disorder later in life. Many of these “idiopathic” cases may be due to 
autoimmune attack on the stem cell population. Secondary aplastic anemia can be 
caused by toxic damage to the marrow by radiation or chemicals (benzene, DDT, 
chemotherapy drugs, gold, etc.) or secondary to viral infection (e.g., EBV) [4].
Discovery of numerous genes incriminated in pathogenesis of Fanconi anemia 
and other inherited bone marrow failure syndromes has made great evolution in 
understanding the mechanism of DNA repair, telomere and telomerase enzyme 
action as well as many other biology secrets. Also, the relationship between the 
development of some types of cancers and presence of bone marrow failure syn-
dromes may explains the etiology of these cancers and multiple birth defects [5].
In this disorder, we expect to see declines in all cell counts (pancytopenia) with 
low reticulocyte counts. Aplastic anemia has been transformed from a near death 
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sentence to a disease with hope and cure in 90% of patients. Due to the emergence 
of advanced supportive care, immunosuppressive therapies and hematopoietic 
stem cell transplantation, this can result in 80% long term survival. In the absence 
of an HLA-matched sibling, allogeneic BMT can also be performed using an HLA-
matched, unrelated donor or stem cells derived from umbilical cord blood [6].
The hemolytic anemias, have multiple causes, and the clinical presentation that 
can be differ according to the etiology. Many laboratory tests and specialized one 
can detect the cause of hemolysis, to reach specific diagnosis. With advancement in 
electrophoretic and other biochemical techniques, hemoglobinopathies are being 
identified now which were not previously possible. There are differences in the 
management of various types of hemolytic anemias [7].
Hemoglobinopathies requiring long life transfusion program to maintain a safe 
hemoglobin level for hemodynamic stability such as in thalassemia major and sickle 
cell anemia frequently had marked facial characteristics with broad cheekbones 
along with organ damage and failure, particularly of the heart, liver, beta cells of 
the pancreas and other tissues due to secondary hemochromatosis because of exces-
sive iron deposition. The clinical findings attributed to extramedullary hematopoi-
esis are essentially of historic interest because of the development and widespread 
use of proper transfusion and chelation regimens.
Sickle cell disease (SCD) is one of the most frequent inherited genetic blood 
disorders in the world. It predominantly affects people of African ancestry (about 
80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa) as well 
as people with Hispanic background and individuals from the Middle East, India, 
and Mediterranean regions [8]. The disease was first described in the medical 
literature by the American physician James B. Herrick in 1910 [9]. Sickle cell disease 
is an autosomal-recessive disease caused by a point mutation in the hemoglobin beta 
gene found on chromosome 11p15.5, Several subtypes exist, depending on the exact 
mutation in each hemoglobin gene, and results in a number of health problems, for 
example, attacks of pain “sickle cell crisis,” feet, anemia, bacterial infection, acute 
chest syndrome, pulmonary hypertension, stroke, cardiac, CNS, gastrointestinal 
involvement and nephropathy which is not only a chronic comorbidity but is also 
one of the leading causes of mortality. Significant advances in prophylactics and 
therapy achieved improved survival among children with sickle cell disease, with 
the majority of children attaining adulthood [10]. However, The average life expec-
tancy in the developed world is 40–60 years with only 35.0% surviving beyond age 
35 years was reported by the Centers for Disease Control (CDC).
Problems in sickle cell disease typically begin around 5–6 months of age. 
Knowledge of the natural progression of the disease, as well as identification of 
persons at risk, allows for timely intervention and improved outcomes. The search 
for biomarkers for the early diagnosis of the disorder and its outcomes is an area 
of intense contemporary research [11]. Our understanding of the basic science of 
molecular biology, oncology, genetics, and the management of several oncologic 
conditions made a huge evolution in the field of pediatric oncology. The previous 
decade was almost associated with fatal outcomes have changed a lot and replaced 
by an era in which most childhood cancers are cured.
This has been made possible not only because of advances in chemotherapeutic 
regimen but also, because of the parallel development of radiodiagnosis, radio-
therapy, surgery as well as supportive care such as the pre-emptive use of antibiotics 
and blood product therapy.
There is greatest variation in childhood cancer incidence internationally, when 
comparing developed countries to developing ones. It is estimated that childhood 
cancer has an incidence of more than 175,000 per year, and a mortality rate of 
approximately 96,000 per year. In developed countries, childhood cancer has a 
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mortality of approximately 20% of cases. In low income countries, on the other 
hand, mortality ranges from 80–90%. This may attributed to different modalities 
in cancer diagnosis, differences in risk factors among different ethnic population 
subgroups as well as differences in reporting. In children aged 0–14 years incidence 
rates range from less than 100 per million in areas of sub-Saharan Africa and India to 
more than 150 per million in some populations of North America and Europe [12].
Familial and genetic factors are identified in 5–15% of childhood cancer cases. Many 
epidemiological studies have reported the effects of cancer genetics, family pedigrees 
and penetrance, and identified subtypes of certain cancers and their implications for 
treatment and prognosis. In addition, the study of certain genetic diseases that increase 
the risk of malignancy in childhood has led to understanding the genetics of cancer [13].
Survival from childhood cancer is no longer rare, and people who have been 
cured of cancer during childhood should be accepted as normal members of society. 
The overall survival rate for children’s cancer has increased from 10% to nearly 
80% today, and it is considered one of the major success stories of medicine in the 
twenty-first century. Improvements in the survival rates of leukemias, Hodgkin 
lymphoma, gonadal, and renal tumors have been notable successes. On the other 
hand, Overall mortality has decreased by 50% between 1975 and 2010 [14, 15].
Improvements in survival rate has led to the new challenge of caring for a growing 
number of cancer survivors. The most ominous late effect of pediatric cancer treat-
ment is a second malignancy, for example, the risk of a second malignancy appears 
15–20 years after an initial diagnosis of acute lymphoblastic leukemia is approxi-
mately 10% [16]. Many risk factors such as environmental factors, treatment and 
hereditary factors have been incriminated in second cancer. For example, the risk of 
acute myeloid leukemia in subject with the 9:11 translocation is approximately 3–6% 
within 5 years of chemotherapy that includes alkylating agent therapy or high-dose 
etoposide according to the dose and type of in addition to exposure to diagnostic 
radiation in utero has been associated with an increased risk of childhood cancer [17].
Contemporary Pediatric Hematology and Oncology covers many aspects of 
research and patient management within the area of blood disorders and malignant 
diseases in children. Of interest are clinical studies as well as basic and translational 
research reports regarding pathogenesis, genetics, molecular diagnostics, pharma-
cology, molecular targeting, standard and novel therapies for the most common 
blood disorders and childhood cancer. This book intends to provide the reader with 
a comprehensive overview on today’s practices and tomorrow possibilities about the 
most important pediatric hematological and oncological diseases.
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